Global financial centres may have their hedge funds but Tokyo has an Edge fund, too. Established two years ago by the Japanese capital city’s oldest university, it is one sign of how initiatives around biotechnology in the country are gathering pace.
With $83m in initial funding from a range of mainstream Japanese financial institutions, the University of Tokyo Edge Capital Company has so far invested $18m in some 16 high-tech campus start-ups, half of which are in the pharmaceutical sector.
